John H. Tucker - Oct 7, 2022 Form 4 Insider Report for scPharmaceuticals Inc. (SCPH)

Role
President and CEO, Director
Signature
/s/ John H. Tucker
Stock symbol
SCPH
Transactions as of
Oct 7, 2022
Transactions value $
-$51,234
Form type
4
Date filed
10/11/2022, 06:06 PM
Previous filing
Feb 1, 2022
Next filing
Jan 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SCPH Common Stock Options Exercise +42.3K +89.97% 89.2K Oct 7, 2022 Direct F1
transaction SCPH Common Stock Tax liability -$51.2K -10.3K -11.53% $4.98 78.9K Oct 7, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SCPH Restricted Stock Units Options Exercise $0 -42.3K -100% $0.00* 0 Oct 7, 2022 Common Stock 42.3K Direct F1, F3
transaction SCPH Stock Option (right to buy) Award $0 +42.3K $0.00 42.3K Oct 7, 2022 Common Stock 42.3K $3.25 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.
F3 On February 25, 2019, the Reporting Person was granted 84,500 restricted stock units (the "RSUs"). One half (1/2) of the RSUs previously vested upon the Issuer's submission of a New Drug Application ("NDA") for its product candidate, FUROSCIX, and the remaining one half (1/2) shall vest upon the Food & Drug Administration's (the "FDA") approval of the NDA. On October 7, 2022, the performance criteria for the second half of the grant was met and 42,250 shares vested. The RSUs have no expiration date.
F4 On February 25, 2019, the Reporting Person was granted an option to purchase 84,500 shares of common stock. One half (1/2) of the shares previously vested upon the Issuer's submission of an NDA for its product candidate, FUROSCIX, and the remaining one half (1/2) shall vest upon the FDA's approval of the NDA. On October 7, 2022, the performance criteria for the second half of the grant was met and 42,250 shares vested.